CA2196207A1 - Identification of a human cytomegalovirus gene involved in down-regulation of mhc class i heavy chain expression - Google Patents

Identification of a human cytomegalovirus gene involved in down-regulation of mhc class i heavy chain expression

Info

Publication number
CA2196207A1
CA2196207A1 CA002196207A CA2196207A CA2196207A1 CA 2196207 A1 CA2196207 A1 CA 2196207A1 CA 002196207 A CA002196207 A CA 002196207A CA 2196207 A CA2196207 A CA 2196207A CA 2196207 A1 CA2196207 A1 CA 2196207A1
Authority
CA
Canada
Prior art keywords
regulation
mhc class
heavy chain
identification
chain expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002196207A
Other languages
French (fr)
Other versions
CA2196207C (en
Inventor
Thomas R. Jones
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
Original Assignee
Thomas R. Jones
American Cyanamid Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomas R. Jones, American Cyanamid Company filed Critical Thomas R. Jones
Priority to CA002328638A priority Critical patent/CA2328638A1/en
Publication of CA2196207A1 publication Critical patent/CA2196207A1/en
Application granted granted Critical
Publication of CA2196207C publication Critical patent/CA2196207C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/245Herpetoviridae, e.g. herpes simplex virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01DNA viruses
    • C07K14/03Herpetoviridae, e.g. pseudorabies virus
    • C07K14/04Varicella-zoster virus
    • C07K14/045Cytomegalovirus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04Inactivation or attenuation; Producing viral sub-units
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5156Animal cells expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5254Virus avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16111Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16121Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16111Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16111Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16111Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16141Use of virus, viral particle or viral elements as a vector
    • C12N2710/16143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16111Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16151Methods of production or purification of viral material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16111Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16161Methods of inactivation or attenuation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16111Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16161Methods of inactivation or attenuation
    • C12N2710/16162Methods of inactivation or attenuation by genetic engineering

Abstract

Infection of human fibroblast cells with human cytomegalovirus (HCMV) causes down-regulation of cell surface expression of MHC class I. A recombinant mutant HCMV which fails to down-regulate class I heavy chain expression is described. A method of controlling down-regulation of MHC class I expression in a cytomegalovirus infected cell, a pharmaceutical composition, a vaccine composition, a method of preventing or reducing susceptibility to acute cytomegalovirus in an individual, and a virus based gene therapy vector are also described.
CA002196207A 1994-07-29 1995-07-31 Identification of a human cytomegalovirus gene involved in down-regulation of mhc class i heavy chain expression Expired - Fee Related CA2196207C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002328638A CA2328638A1 (en) 1994-07-29 1995-07-31 Identification of a human cytomegalovirus gene involved in down-regulation of mhc class i heavy chain expression

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/282,696 US5846806A (en) 1994-07-29 1994-07-29 Identification of a human cytomegalovirus gene region involved in down-regulation of MHC class I heavy chain expression
US08/282,696 1994-07-29
PCT/US1995/009799 WO1996004384A1 (en) 1994-07-29 1995-07-31 Identification of a human cytomegalovirus gene involved in down-regulation of mhc class i heavy chain expression

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA002328638A Division CA2328638A1 (en) 1994-07-29 1995-07-31 Identification of a human cytomegalovirus gene involved in down-regulation of mhc class i heavy chain expression

Publications (2)

Publication Number Publication Date
CA2196207A1 true CA2196207A1 (en) 1996-02-15
CA2196207C CA2196207C (en) 2002-04-30

Family

ID=23082718

Family Applications (3)

Application Number Title Priority Date Filing Date
CA002195668A Expired - Fee Related CA2195668C (en) 1994-07-29 1995-07-28 Identification of a human cytomegalovirus gene region involved in down-regulation of mhc class i heavy chain expression
CA002328638A Abandoned CA2328638A1 (en) 1994-07-29 1995-07-31 Identification of a human cytomegalovirus gene involved in down-regulation of mhc class i heavy chain expression
CA002196207A Expired - Fee Related CA2196207C (en) 1994-07-29 1995-07-31 Identification of a human cytomegalovirus gene involved in down-regulation of mhc class i heavy chain expression

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CA002195668A Expired - Fee Related CA2195668C (en) 1994-07-29 1995-07-28 Identification of a human cytomegalovirus gene region involved in down-regulation of mhc class i heavy chain expression
CA002328638A Abandoned CA2328638A1 (en) 1994-07-29 1995-07-31 Identification of a human cytomegalovirus gene involved in down-regulation of mhc class i heavy chain expression

Country Status (11)

Country Link
US (6) US5846806A (en)
EP (2) EP0775209A1 (en)
JP (2) JP4036469B2 (en)
KR (2) KR970704884A (en)
AU (2) AU709552B2 (en)
CA (3) CA2195668C (en)
FI (2) FI970352A (en)
MX (1) MX9700676A (en)
NO (2) NO970369L (en)
NZ (2) NZ290718A (en)
WO (2) WO1996004383A1 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997032605A1 (en) * 1996-03-08 1997-09-12 Massachusetts Institute Of Technology Cytomegalovirus nucleic acids encoding proteins having normal or altered class i mhc binding and treatment of diseases
PT966301E (en) * 1996-07-31 2005-06-30 Ortho Mcneil Pharm Inc IDENTIFICATION OF HUMAN CITOMEGALOVIRUS GENES INVOLVED IN THE NEGATIVE ADJUSTMENT OF MHC HEAVY CHAIN EXPRESSION CLASS I
WO1998031813A1 (en) * 1997-01-17 1998-07-23 Roche Diagnostics Gmbh Inhibitors of antigen presentation by mhc class i molecules
WO1998047914A2 (en) * 1997-04-18 1998-10-29 Roche Diagnostics Gmbh Us6 gene from the human cytomegalovirus (hcmv)
EP1045920A1 (en) * 1998-01-14 2000-10-25 Human Gene Therapy Research Institute Nucleotide expression systems with reduced immunogenicity for use in gene therapy
US6100008A (en) * 1998-09-14 2000-08-08 Ppg Industries Ohio, Inc. Positive photoresist with improved contrast ratio and photospeed
WO2000046361A1 (en) * 1999-02-02 2000-08-10 Oregon Health Sciences University Inhibition of the mhc class ii antigen presentation pathway and presentation to cd4+ cells
WO2002018954A2 (en) 2000-08-30 2002-03-07 Chemocentryx, Inc. Inhibition of cmv infection and dissemination
WO2002062296A2 (en) 2001-02-02 2002-08-15 Chemocentryx, Inc. Methods and compositions useful for stimulating an immune response
US20030118568A1 (en) * 2001-12-18 2003-06-26 Board Of Trustees Of The University Of Arkansas Viral stealth technology to prevent T cell-mediated rejection of xenografts
US20040228842A1 (en) * 2003-02-27 2004-11-18 Shan Lu Compositions and methods for cytomegalovirus treatment
KR20050093003A (en) * 2004-03-17 2005-09-23 이재본 Micro turbine generator
JP2010517544A (en) 2007-02-07 2010-05-27 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ Recombinant antigen of human cytomegalovirus (HCMV)
WO2009073330A2 (en) * 2007-11-12 2009-06-11 The Trustees Of The University Of Pennsylvania Novel vaccines against multiple subtypes of influenza virus
CA2793959C (en) * 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
PT2772265T (en) 2010-05-14 2018-04-20 Univ Oregon Health & Science Recombinant hcmv and rhcmv vectors and uses thereof
AU2012267786B2 (en) 2011-06-10 2017-08-03 Oregon Health & Science University CMV glycoproteins and recombinant vectors
WO2014138209A1 (en) 2013-03-05 2014-09-12 Oregon Health & Science University Cytomegalovirus vectors enabling control of t cell targeting
MA39818A (en) 2014-03-30 2017-02-08 Benevir Biopharm Inc Exogenous tap inhibitor "armed" oncolytic viruses and therapeutic uses thereof
BR112017000696B1 (en) 2014-07-16 2023-10-03 Oregon Health & Science University ISOLATED POLYNUCLEOTIDE
CN114317611A (en) * 2015-02-10 2022-04-12 俄勒冈健康与科学大学 Methods and compositions useful for generating atypical CD8+ T cell responses
US10688164B2 (en) 2015-11-20 2020-06-23 Oregon Health & Science University CMV vectors comprising microRNA recognition elements
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
CA3028827A1 (en) 2016-06-22 2017-12-28 Aeras Recombinant cytomegalovirus vectors as vaccines for tuberculosis
JP2019531745A (en) 2016-10-18 2019-11-07 オレゴン ヘルス アンド サイエンス ユニバーシティ Cytomegalovirus vector that induces T cells restricted by major histocompatibility complex E molecules
EP3697806A4 (en) 2017-10-17 2021-10-27 International AIDS Vaccine Initiative, Inc. Tuberculosis antigen cassettes
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
US11857622B2 (en) 2020-06-21 2024-01-02 Pfizer Inc. Human cytomegalovirus GB polypeptide

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4058598A (en) * 1974-10-18 1977-11-15 Harold Stern Cytomegalovirus attenuation method and vaccine
US4689225A (en) * 1984-11-02 1987-08-25 Institut Merieux Vaccine for cytomegalovirus
US4877612A (en) * 1985-05-20 1989-10-31 Frank M. Berger Immunological adjuvant and process for preparing the same, pharmaceutical compositions, and process
US4877737A (en) * 1985-09-06 1989-10-31 Prutech Research And Development Partnership Attenuated pseudorabies virus which has a deletion in at least a portion of a repeat sequence and vaccine containing same
US5273876A (en) * 1987-06-26 1993-12-28 Syntro Corporation Recombinant human cytomegalovirus containing foreign gene
WO1988010311A1 (en) * 1987-06-26 1988-12-29 Syntro Corporation Recombinant human cytomegalovirus containing foreign gene and use thereof
AU3550489A (en) * 1988-05-09 1989-11-29 Children's Hospital Incorporated, The Vectors encoding hcmv glycoprotein and expression products
SG49046A1 (en) * 1991-07-05 1998-05-18 American Cyanamid Co Method for identifying non-essential genes of the human cytomegalovirus genome and for screening for inhibitors of human cytomegaloverirus

Also Published As

Publication number Publication date
JPH10506268A (en) 1998-06-23
WO1996004383A1 (en) 1996-02-15
NO970370D0 (en) 1997-01-28
NO970369D0 (en) 1997-01-28
AU709552B2 (en) 1999-09-02
AU3153595A (en) 1996-03-04
CA2195668C (en) 2004-09-21
FI970352A0 (en) 1997-01-28
US5846806A (en) 1998-12-08
AU3274595A (en) 1996-03-04
JP4036469B2 (en) 2008-01-23
NO970369L (en) 1997-03-21
EP0772681A1 (en) 1997-05-14
KR970704883A (en) 1997-09-06
CA2196207C (en) 2002-04-30
KR970704884A (en) 1997-09-06
US5753476A (en) 1998-05-19
FI970352A (en) 1997-01-28
NZ290718A (en) 1999-03-29
CA2195668A1 (en) 1996-02-15
US5843458A (en) 1998-12-01
US5906935A (en) 1999-05-25
MX9700710A (en) 1997-09-30
NO970370L (en) 1997-03-24
FI970351A (en) 1997-01-28
US5908780A (en) 1999-06-01
JPH10503378A (en) 1998-03-31
AU708983B2 (en) 1999-08-19
NZ291571A (en) 1999-01-28
CA2328638A1 (en) 1996-02-15
MX9700676A (en) 1997-04-30
US5720957A (en) 1998-02-24
EP0775209A1 (en) 1997-05-28
FI970351A0 (en) 1997-01-28
WO1996004384A1 (en) 1996-02-15

Similar Documents

Publication Publication Date Title
CA2196207A1 (en) Identification of a human cytomegalovirus gene involved in down-regulation of mhc class i heavy chain expression
AU4032893A (en) Human papilloma virus genes and their use in gene therapy
BR9712366A (en) Herpes simplex hsv2 gd2 gene isolated, plasmid comprising the same, and processes to induce an immune response against hsv2 gd2 in an individual, to treat an individual who is infected with hsv, and to prevent an individual from becoming infected with hsv
FR2712603B1 (en) Recombinant viruses, preparation and use in gene therapy.
GB2217718B (en) Recombinant viruses,vaccines containing them and in vitro cell cultures thereof
AU3066992A (en) Cellular nucleic acid binding protein and uses thereof in regulating gene expression and in the treatment of aids
PT92931A (en) Treatment of host cells - for infection or hyper-proliferative disorder characterised by presence of trans-activating factor, using cis-acting factor
CA2072627A1 (en) Recombinant herpes simplex viruses vaccines and methods
AU3824595A (en) Recombinant negative strand RNA virus expression systems and vaccines
FR2647808B1 (en) RECOMBINANT POXVIRUS AND HERPES VIRUS VACCINE CONTAINING THE POXVIRUS
AUPN477695A0 (en) Gene therapy
EP0564539A4 (en) Sustained and continuous production of high titers of recombinant viral vectors and transduced target cells for use in gene therapy
CA2130360A1 (en) Sulfonic Acid Derivatives in the Treatment of Viral Diseases
FR2702152B1 (en) Recombinant viruses and their use in gene therapy.
CA2124769A1 (en) Recombinant foamy virus vectors for medicinal and diagnostic uses, and processes for preparing recombinant foamy virus vectors
FR2712602B1 (en) Recombinant viruses, preparation and use in gene therapy.
BR9806866A (en) Expression cassette and its use, expression cassette strain, nucleic acid vector, viral strain, pharmaceutical composition, and, processes to study the function of one or more heterologous genes in a eukaryotic cell, to produce an hsv strain, for treating the human or animal body and for performing gene therapy on a human or animal, and, vaccine.
DE3782867D1 (en) Human cytomegalovirus phospho-protein
AU5008296A (en) Recombinant viruses expressing lecithin-cholesterol acyltransferase, and uses thereof in gene therapy
AU7665396A (en) Recombinant viruses containing mobile genetic elements and methods of use in gene therapy
IL88371A0 (en) Directed integration of genes into a plant genome and recombinant dna,expression vectors and host cells used therefor
AU1347292A (en) Methods of transcriptionally modulating gene expression of viral genes and other genes
NZ324157A (en) Conditionally replicating viral vectors and their use in treating HIV
ATE360061T1 (en) REPLICATION-DEFECTIVE MUTANTS OF HERPES VIRUS
AU3410889A (en) Novel recombinant vaccinia virus expression vectors and method of selecting same

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed